The most boring breakout category in global agritech, and possibly the most important, is biologicals. The term covers a family of input products built around living organisms or natural compounds rather than synthetic chemistry — bio-fertilizers based on nitrogen-fixing bacteria, biocontrols using fungi or insects to manage pests, biostimulants that improve plant resilience without adding nutrients in the chemical fertilizer sense. Globally, the category is growing at 10 to 14 percent annually, and recent distributor surveys indicate that the overwhelming majority of agri-input retailers plan to expand their biological offerings in 2026.
This is not a fringe organic-farming story. The largest agrochemical companies in the world — Bayer, Syngenta, BASF, UPL — have built or acquired serious biological portfolios over the past five years. The thesis is that biologicals will not replace conventional inputs but will sit alongside them in integrated programs, and that growers running biological-conventional hybrids will outcompete pure-conventional growers on yield, soil health, and cost.
For India, the question is not whether biologicals matter. The market is already substantial and growing. The question is whether the existing distribution structure can actually deliver these products to the farms that need them, in a form that performs.
What biologicals actually are, in operational terms
Three subcategories matter for Indian agritech, and they have very different operational requirements.
Bio-fertilizers. Microbial inoculants — Rhizobium, Azotobacter, Phosphate Solubilizing Bacteria, Mycorrhizae — that biologically fix or unlock nutrients in soil. These have been promoted in India for decades, with mixed results, primarily because product quality varied wildly and storage conditions destroyed efficacy before the product reached the field. The newer generation of products is meaningfully better, but the distribution problem has not been solved.
Biocontrols. Living organisms — Trichoderma, Pseudomonas, Bacillus species, predator insects — used to manage pests and diseases. The Indian market for these is real but small relative to chemical pesticides. Commercial supply chains have matured significantly over the past two years, but adoption is concentrated among progressive growers and certified organic farms.
Biostimulants. Seaweed extracts, humic and fulvic acids, plant hormones, protein hydrolysates — products that improve plant stress tolerance and growth without being primary nutrient sources. This is the fastest-growing biological subcategory globally because the regulatory bar is lower than for pesticides, and the products genuinely work in stress conditions, which are increasing.
Why India is well positioned in manufacturing
One of the surprises in this category is that India is already a meaningful manufacturer of biologicals, both for domestic use and for export. The country has a large microbiology research base, dozens of biocontrol production facilities, and a growing seaweed extract industry centred on Tamil Nadu and Gujarat. Companies like IPL Biologicals, T Stanes, and Multiplex have built scaled operations. Several Indian biological manufacturers export to Europe and the Middle East at prices their European competitors cannot match.
So the bottleneck is not production. It is what happens between the factory and the field.
The three distribution problems
Cold chain. Live microbial products lose efficacy when stored above certain temperatures, typically 25 to 30 degrees Celsius. Indian agri-input distribution operates predominantly without refrigeration. A product manufactured perfectly in Pune can be dead by the time it reaches a retailer in Jhansi, where it sat on a shelf in 40-degree heat for three weeks. The retailer sells it, the farmer applies it, and nothing happens. The farmer concludes biologicals do not work, and word spreads.
The technical fix exists. Improved formulations, talc-based carriers, and shelf-stable strains have improved dramatically in the past five years. The distribution fix has not kept pace. Companies that build their own cold-chain or near-cold-chain delivery — typically by selling direct or through tightly managed FPO networks — see dramatically better field outcomes than those selling through the open retail market.
Counterfeit and quality dilution. The Indian biological input market has a long history of counterfeit and adulterated products. A 2024 quality survey conducted by an industry association found that a significant share of biological samples drawn from retail outlets failed efficacy testing. Some were diluted. Some were dead. Some were entirely the wrong organism. A farmer who tries three counterfeit Trichoderma products in a row reasonably concludes biologicals are a scam, regardless of what the legitimate market is selling.
Farmer trust deficit. Decades of mixed results — partly real product problems, partly inappropriate application advice, partly the distribution issues above — have left many Indian farmers skeptical of biologicals as a category. This is not a marketing problem that better messaging fixes. It is an outcome problem that only consistent field performance fixes, over multiple seasons, in front of farmers who watch their neighbours.
"The product technology has caught up. The distribution model has not. Companies that fix the second problem will own this category in India for the next decade."
That observation came from a category head at a multinational agrochemical company with significant biological investments in India. It captures the strategic situation accurately. Indian biologicals do not need better R&D in the immediate term. They need better roads to the farm.
Who is positioned to solve the distribution problem
Four models are emerging, and each has different strengths.
FPO-led distribution. Biological products distributed through FPOs to their own farmer-members bypass much of the open-market quality risk. The FPO has a direct interest in product performance because the farmers are also output suppliers. Cold chain is shorter and more controllable. Trust is pre-existing. This is probably the most promising model for organic and biological-heavy programs, and the FPOs running it well are quietly outperforming conventional advisory in their clusters.
Direct-to-farmer platforms. BharatAgri, AgroStar, and DeHaat are increasingly able to control the full path from manufacturer to farmer, including storage conditions and application advisory. For biostimulants and biocontrols specifically, this model is starting to work at scale. The Achilles heel remains the last-mile cold storage problem, which is improving but unsolved.
Crop-specific input bundles. Specialty biological programs bundled with seed and conventional inputs for specific high-value crops — grapes, pomegranates, vegetables, banana — have a credible commercial track record. The Indian table grape industry's adoption of biological pest management is the clearest case study. The bundle provides accountability for outcomes that loose retail biological sales never can.
Government-led programs. Schemes like Paramparagat Krishi Vikas Yojana and the National Mission for Sustainable Agriculture have created some demand, but the execution quality varies sharply by state. Andhra Pradesh's natural farming program is the most-cited example of state-led biological adoption working at scale. Replicating it elsewhere has been difficult.
The buyer's read
If you procure biologicals for an FPO, a corporate farming operation, or a distribution network, three filters separate products that will perform from those that will disappoint.
One: how the product is stored after manufacture. Ask the supplier to walk you through the temperature-controlled chain from factory to your warehouse. If they cannot describe it concretely, the product is at risk regardless of how good it was when it left the factory.
Two: third-party efficacy testing. Reputable biological manufacturers are willing to share independent lab results showing colony-forming units or active ingredient concentration at the time of sale. Suppliers who deflect this question should be deprioritized.
Three: application protocol specificity. A biological product that performs well requires specific application conditions — timing, water pH, mixing order with other inputs, soil temperature. Suppliers who provide vague application guidance are setting up the product to underperform in the field. The good suppliers provide crop-specific protocols with the supply.
Biologicals are the global agritech category most likely to transform Indian farming over the next decade, more than drones, robotics, or any single piece of hardware. Whether that transformation actually happens depends less on the products and more on whether someone solves the boring problems of cold chain, quality control, and field-level trust. The first companies to do that will quietly own one of the largest input categories in the country.